Radiographic, Clinical and Patient Outcomes in a Multicenter, Open-label Phase IV Randomized Trial of Earlier Adalimumab Introduction Therapy Versus Later Introduction as Per Standard of Care After Initial Methotrexate Failure in Early Rheumatoid Arthritis Patients

Trial Profile

Radiographic, Clinical and Patient Outcomes in a Multicenter, Open-label Phase IV Randomized Trial of Earlier Adalimumab Introduction Therapy Versus Later Introduction as Per Standard of Care After Initial Methotrexate Failure in Early Rheumatoid Arthritis Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2016

At a glance

  • Drugs Adalimumab (Primary) ; Disease-modifying antirheumatics; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RADAR
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jan 2015 Planned End Date changed from 1 Jul 2021 to 1 Jul 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top